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Background:  Diabetes mellitus is a well-known risk factor for recurrent adverse cardiac events in patients taking dual antiplatelet therapy 
(DAPT) with aspirin and clopidogrel. Previous studies have demonstrated higher rates of clopidogrel resistance in diabetic patients. 
However, conflicting reports exist about the role of glycemic control on clopidogrel response, and, to the best of our knowledge, in non-
diabetic individuals, the influence of glucose levels on the clopidogrel response is unknown.
methods:  We analyzed 85 patients with chronic coronary artery disease (CAD) treated with aspirin 100 mg daily chronically. This is a pre-
specified analysis from a double-blind randomized study, which tested the interaction between clopidogrel and ranitidine or omeprazole. 
All patients had their platelet aggregability measured with the VerifyNow P2Y12TM test in three moments: baseline, after one week of 
clopidogrel therapy 75 mg daily, and after one week of randomization to omeprazole 20 mg BID or ranitidine 150 mg BID. Here we report 
the interaction of these results with glycated hemoglobin and fasting plasma glucose, which were measured at the first medical visit 
(baseline).
results:  The results are shown in the following table.
Conclusion:  In patients with stable CAD, high glucose levels reduce clopidogrel efficacy. However, this influence is attenuated when 
omeprazole is added to clopidogrel therapy.
Table: Comparison of platelet aggregability in P2Y12 Reaction Units (PRU)
Results:  Mean ± SD PRU
Baseline
(n= 85) After clopidogrel (n = 85) Ranitidine group (n= 44)
Omeprazole group
(n = 41)
HbA1c <7 % 219.04 ± 63.86
254.35 ± 68.42
(P = 0.036)
147 ± 77.18
190.83 ± 68.43
(P = 0.032)
153.17 ± 77.86
203.60 ± 73.22
(P = 0.073)
163.48 ± 70.68
184.50 ± 52.43
(P = 0.393)HbA1c ≥7 %
Glucose <120 mg/dL 219.76 ± 65.29
249.04 ± 65.57
(P = 0.057)
145.11 ± 76.26
189.17 ± 73.32
(P = 0.019)
147.31 ± 72.75
198.75 ± 81.8
(P = 0.035)
169.70 ± 79.96
179.64 ± 51.37
(P = 0.70)Glucose ≥120 mg/dL
P-value for comparison between groups (HbA1c HbA1c < 7 % vs HbA1c ≥ 7 % and plasma glucose < 120 mg/dL vs glucose ≥ 120 mg/dL
:
